A Trial of Grazax in Subjects With Hayfever

ALK-Abelló A/S329 enrolled

Overview

The trial is performed to evaluate the efficacy and safety of specific immunotherapy with Grazax for treatment of grass pollen induced allergy.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

329

Conditions

Allergy

Interventions

GrazaxDRUG

Tablets 75,000 SQT and matching placebo. One tablet daily.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * History of grass pollen allergy * Positive skin prick test to grass * Positive specific IgE to grass Exclusion Criteria * FEV1 \<70% of predicted value

Locations (1)

CompleWare Corporation

Iowa City, Iowa, United States

Outcomes

Primary Outcomes

Recording of allergy symptoms

Time frame: Grass pollen season 2007

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.